ok dumb question but most of what i’m reading about inosine is longevity-focused (energy metabolism, aging, etc). but the 2,3-bpg angle (oxygen delivery to cells) got me thinking… has anyone looked at using it for localized healing? like if you’re running bpc-157 or other peptides for a torn tendon/labrum, would inosine theoretically help oxygen availability at the actual repair site? iirc the bpg-pnp axis is about red cell metabolism, which is systemic. so maybe it doesn’t matter where your injury is. but maybe local circulation at an injury site is bottlenecked and oxygen delivery is the limiting factor vs the peptide itself? curious if anyone’s stacked inosine with repair peptides and noticed anything, or just overthinking this?
2,3-BPG is a whole-blood mechanism, so inosine can’t route oxygen preferentially to your labrum vs anywhere else in circulation. That part of your framing is right. Where I’d push back is on oxygen delivery being the actual bottleneck in connective tissue repair. Injured tissue is inflamed, and inflammation drives local blood flow up. You’re generally not running hypoxic at the injury site in the acute or subacute phase. The limiting factor in tendon and labrum healing is more likely collagen synthesis rate and fibroblast signaling, which is the territory BPC addresses. The vascular remodeling evidence is decent too. The energy metabolism angle for inosine is a separate argument from the oxygen delivery angle. Healing fibroblasts need ATP, and there’s a substrate availability case to be made. But those are two distinct mechanisms and worth keeping distinct before stacking another variable on top of an already hard-to-read protocol. Ran BPC for most of last year on a shoulder tear. Never added inosine. Oxygen availability wasn’t the part I was focused on.
Tendon tissue IS hypovascular, so the oxygen-delivery premise isn’t crazy. But inosine’s 2,3-BPG effect operates systemically across all RBCs. You can’t point preferential oxygen unloading at a specific injury site, and that’s the gap in the logic. BPC already promotes angiogenesis as part of its proposed connective tissue repair mechanism, so you’d be layering a systemic O2 modifier onto a compound that’s already working the local vascularization problem. The “oxygen delivery vs the peptide itself” framing treats those as independent variables. They’re probably not, and if BPC hasn’t had time to establish local blood supply yet, inosine isn’t solving that problem from the RBC side anyway.
three weeks in and still seeing localized swelling plus nerve stuff, which makes me skeptical of the “generally not running hypoxic” framing. could be normal healing, but could also mean the site’s circulation hasn’t fully recovered. if oxygen IS limiting even locally, a systemic improvement could still matter.
If you’re already running bpc, the angiogenesis piece is worth adding to this: one of BPC’s documented mechanisms is VEGF upregulation and new vessel formation at the repair site. So it’s theoretically addressing local vascular supply, not just tissue-level signaling. Inosine’s 2,3-BPG effect improves RBC oxygen unloading efficiency systemically, but if capillary infrastructure at a hypovascular tendon is the actual bottleneck, better unloading doesn’t help much when the delivery pathways aren’t there yet. Whether BPC’s angiogenic effect makes inosine redundant in this context, I genuinely don’t know - but that’s the question I’d want to isolate before adding another variable to the stack.
2,3-bpg doesn’t care about your labrum specifically, and you already clocked that part. the bigger problem with the oxygen-delivery hypothesis is that bpc’s mechanism isn’t primarily oxygen-sensitive anyway. it works through growth factor signaling, fibroblast recruitment, angiogenesis. none of those processes are competing for dissolved oxygen at the repair site in a way that a shift in the dissociation curve would move the needle on. tendons are avascular enough that blood getting there at all is the constraint, not how readily the rbc’s let go of what they’re carrying.
The 2,3-BPG angle isn’t wrong, but the bottleneck I’d push back on is assuming oxygen delivery is rate-limiting at a tendon repair site. Tendons are already hypovascular. BPC works partly because it promotes angiogenesis around that hypovascular tissue, so the peptide is addressing the circulation problem directly. Stacking inosine for systemic oxygen efficiency on top of that seems like fixing downstream of the actual constraint. ymmv.
The “nerve stuff” you mentioned is what catches my attention more than the oxygen question. Swelling at three weeks isn’t unusual, but nerve symptoms alongside it usually mean the inflammatory phase is still active around the repair site, not necessarily that circulation is bottlenecked. BPC actually has research behind it on nerve-adjacent repair mechanisms that’s distinct from standard tissue healing, which might be the more relevant piece here than inosine’s 2,3-BPG angle. Worth flagging that specifically with a consultant rather than filing it under probably normal healing.
Not overthinking at all - the local vascular environment at an injury site is genuinely understudied and the question is worth asking. BPC-157’s angiogenic mechanism is actually the answer though: it promotes new vessel formation directly at the repair site, which is the more direct solve for local oxygen availability rather than the systemic 2,3-BPG route. So the two may be addressing the same bottleneck, which makes stacking them less additive than it looks on paper.
the “bottlenecked” framing is actually the part worth pulling on – injured tissue runs higher metabolic demand during active repair AND has compromised microcirculation from edema and inflammation. a systemic rightward shift on the oxygen-hemoglobin dissociation curve via 2,3-BPG could plausibly matter more at a repair site than in healthy tissue precisely because delivery is already impaired there. the complication is bpc already promotes angiogenesis via VEGF pathways, so you might be patching something the peptide is already handling. haven’t stacked inosine with bpc directly, but the oxygen delivery hypothesis isn’t overthinking it.
“local circulation at an injury site is bottlenecked” is the part worth pushing on. Tendons and labrums are hypovascular by design, which is literally why they heal slowly. The 2,3-BPG mechanism improves oxygen offloading to tissue that already has adequate perfusion. It doesn’t generate new vessels. BPC’s known mechanism includes angiogenesis promotion, so if you’re running it, you’re already working that angle from a different direction. Layering inosine on top assumes there are enough red cells reaching the repair site in the first place, which in dense connective tissue isn’t a given regardless of your 2,3-BPG status. The case for inosine systemically is real, the energy metabolism angle has legs. But “oxygen delivery is the local bottleneck in tendon repair” is an assumption, not an established rate-limiter. My bet is fibroblast activity and collagen remodeling timelines are where the actual constraint lives, not oxygen per red cell.
the “oxygen delivery” framing assumes blood is actually reaching the tendon in useful quantity. tendons are hypovascular by design, so if perfusion at the repair site is the real constraint, tweaking 2,3-BPG moves a number on a dissociation curve the tissue can barely see.